Aims To investigate the kinetics of CYP-mediated N-demethylation of methadone in human liver microsomes, and examine the role of stereoselectivity and CYP isoforms involved. Methods The kinetics of 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) formation via N-demethylation of rac-, (R)-and (S)-methadone in human liver microsomes prepared from six liver samples were determined by h.p.l.c., and inhibition of metabolic function was studied using isoform-specific chemical inhibitors and monoclonal antibodies. Microsomes containing expressed CYP3A4, CYP2D6 and CYP2C19 were also used to examine the formation of EDDP. 25% ). There were no statistically significant differences in the inhibition observed between the three substrates. Selective inhibitors of CYP1A2 (furafylline), CYP2A6 (coumarin), CYP2C19 ((S)-mephenytoin), CYP2D6 (quinidine) and CYP2E1 (diethyldithiocarbamic acid sodium salt and monoclonal human CYP2E1 antibodies) had no significant ( P >0.05) effect. Conclusions The N-demethylation of methadone in human liver microsomes is not markedly stereoselective, and is mediated mainly by CYP3A4 with the possible involvement of CYP2C9 and CYP2C19. Thus, the large interindividual variation reported for methadone pharmacokinetics may be due to variability in the expression of these CYP isoforms, and the reported stereoselectivity in the systemic clearance of methadone in vivo is not due to stereoselectivity in N-demethylation.
Introduction in which (R)-methadone has a 10-fold higher affinity at m and d opioid receptors [1] and possesses up to 50 times Rac-methadone is commonly used in the management of chronic pain and as maintenance therapy for the pharmacothe analgesic activity of (S)-methadone in human and animal models of pain [2] . (R)-methadone has also been logical treatment of opioid dependence. Rac-methadone (6-dimethylamino-4,4-diphenyl-3-heptanone) is a chiral shown to prevent the occurrence of opioid withdrawal symptoms, while (S)-methadone is ineffective [3] . Despite this high eudismic ratio, methadone is used as the undergoes spontaneous cyclization and dehydration to form 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP, Figure 1 ), which may then be further Ndemethylated to 2-ethyl-5-methyl-3,3-diphenylpyrroline (EMDP, Figure 1 ) [8] . p-hydroxylation of one aromatic ring has also been reported, resulting in the formation of four diastereomeric compounds collectively referred to as p-hydroxy methadone [8, 10] . After oral dosing, unchanged methadone and EDDP are found in similar amounts in the urine of humans and account for up to 50% of the dose [8, 10] , with only trace amounts of EMDP; other metabolites appear to contribute relatively little to the overall metabolism of methadone [8, 10] , although this has not been well studied, since complete mass balance has not been achieved. The in vitro oxidative metabolism of rac-methadone in human liver microsomes has only recently been described [11] [12] [13] [14] . Iribarne and coworkers [11] reported that racmethadone was N-demethylated by CYP3A4, and that selective inhibitors of CYP2D6, CYP1A2, CYP2C9 had no effect. Based upon experiments with heterologously expressed CYP enzymes they did not rule out the contribution of other CYP450 isoforms. The role of stereoselectivity was not examined.
The aims of the present study were to investigate the CYP-mediated N-demethylation of methadone in human liver microsomes, and to examine the role of stereoselectivity and CYP isoforms involved in each reaction.
Methods

Chemicals
Rac-methadone as the hydrochloride salt, (R)-and (S)-methadone as the free bases (4R,6S)-and (4S,6S)-p hydroxylated methadone ( p-hydroxy methadone) as the hydrochloride salts were obtained from the National Institute of Drug Abuse (Rockville, MD, USA). 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) as the hydroiodide salt and 2-ethyl-5-methyl-3, College, PA, USA). Other materials were obtained from the following sources: furafylline and (S)-mephenytoin (Ultrafine Chemicals, Manchester, England), bovine (R)-methadone having a greater volume of distribution [4] , longer half-life [4], higher total systemic clearance [4] serum albumin (fraction V), butylated hydroxytoluene, chlorzoxazone, coumarin, diethyldithiocarbamic acid and lower plasma protein binding [5, 6] . It is not known whether the stereoselectivity in systemic clearance is due sodium salt (DDC), DL-isocitric acid tri-sodium salt, folin-ciocalteau reagent, isocitrate dehydrogenase (NADP, to metabolism (intrinsic clearance) and/or protein binding.
Methadone metabolism in humans is complex, with type IV), quinidine sulphate, sulphaphenazole, triethylamine and troleandomycin were obtained from Sigma nine metabolites identified [7] [8] [9] ) and anaemia (haemoglobin 9.7 g l −1 ). All tissue samples used were normal on gross respectively. Under these conditions all compounds of interest were baseline resolved, with the exception of the morphology. Microsomes were prepared by differential centrifugation of liver homogenates [15] , and total p-hydroxy methadone diastereomers. In preliminary experiments, EMDP and the p-hydroxy methadone diastermicrosomal protein and cytochrome P450 content of the microsomes were quantified using the methods of Lowry eomers were not observed following microsomal incubation and no further modifications to the h.p.l.c. system and coworkers [16] and Omura & Sato [17] , respectively. Liver samples and microsomal preparations were stored were attempted. Quantification of EDDP was performed with calibration curves consisting of 12 standards over the at −80°C until used. DNA was extracted from the liver tissue for the determination of CYP2D6 and concentration range 0.25-50 mm. Inter-assay variability was monitored with quality control (QC) samples prepared in CYP2C19 genotypes. CYP2D6 alleles screened were CYP2D6*1A, CYP2D6*4A, CYP2D6*4B, duplicate at three concentrations; low (LQC, 0.62 mm), medium (MQC, 1.74 mm) and high (HQC, 12.45 mm). CYP2D6*4C, CYP2D6*4D and CYP2D6*5 [18, 19] . CYP2C19 alleles screened were CYP2C19*1, Inter-assay precision (n=6) was 7.4%, 3.6% and 0.7%, while interassay inaccuracy (n=6) was −3.0%, +4.8% CYP2C19*2 and CYP2C19*3 [20] . Results of the genotyping corresponded to the extensive metaboliser and −3.1% for the LQC, MQC and HQC, respectively. Similarly intra-assay precision (n=6) was 6.4%, 6.2% and phenotype for both CYP isoforms in all liver samples. Genotyping of HLS# 16 was not possible due to 3.9%, while intra-assay inaccuracy (n=6) was −8.6%, −0.2% and −3.2% for the LQC, MQC and HQC, insufficient tissue.
respectively. The assay was both precise and accurate at the limit of quantification (0.25 mm) with coefficient of Microsomal incubations variation and inaccuracy (n=3) below 10%. Incubations were performed in duplicate at 37°C in a shaking water bath for 45 min. The incubates of 200 ml Inhibition studies with chemical inhibitors final volume contained 50 mm sodium phosphate buffer ( pH 7.4), NADPH generating system (1 mm NADP, Microsomes from three human liver samples (HLS# 5, 16 and 21) were used in duplicate to examine the 1 unit ml −1 isocitrate dehydrogenase, 5 mm magnesium chloride), substrate (minimum of 10 concentrations, final inhibition of EDDP formation from rac-, (R)-and (S)-methadone. Substrates were incubated at a concenconcentration range of 1-1500 mm for rac-methadone and 1-1250 mm for (R)-and (S)-methadone) and 100 mg tration equal to their respective K m values for that particular liver sample. Chemical inhibitors considered to in duplicate to examine the formation of EDDP from (R)-and (S)-methadone. Microsomes containing expressed be specific for various isoforms [21] were coumarin (CYP2 A6, 100 mm), DDC (CYP2E1, 100 mm and CYP isoforms were used according to the manufacturers directions. Incubation conditions did not alter from the 10 mm), furafylline (CYP1A2, 100 mm), quinidine (CYP2D6, 1 mm), sulphaphenazole (CYP2C9, 100 mm), kinetic study, except that the CYP enzymes were kept ice cold until addition to the reaction mixture. Amounts of troleandomycin (CYP3A, 1, 10 and 100 mm), ketoconazole (CYP3A, 0.1, 1 and 100 mm ), and (S)-mephenytoin CYP enzyme used were kept constant (6 pmol P450/incubation), which resulted in amounts of protein (CYP2C19, 100 mm). In addition diazepam (CYP3A/2C19, 100 mm [22] ) and fluoxetine similar to that used for the human liver microsomes (100 mg). Reaction velocities were compared to that (CYP2D6/3A, 100 mm [23] ) were also tested as they are often coadministered to individuals in methadone mainobtained from a single human liver sample (HLS#5), which was incubated at the same time as the expressed tenance therapy. Chlorzoxazone (100 mm) and omeprazole (100 mm) were also tested. Incubation conditions did enzyme. Substrate concentrations were fixed at 200 mm. not alter from the kinetic study, except that the mechanism-based inhibitors DDC, furafylline and troleanSecondary metabolism of EDDP domycin required 20 min preincubation prior to the The formation of EMDP from EDDP via a second Naddition of substrate. Inhibitors were dissolved in various demethylation reaction was also examined. EDDP was solvents due to differences in solubility. Of those not incubated at a concentration of 1 mm in a single made up in water, dimethylsulphoxide was used to microsomal preparation under conditions identical to dissolve furafylline and sulphaphenazole with final those used for the methadone incubations. Analysis of dimethylsulfoxide concentrations of 1.7% and 0.5%, the sample for EMDP was performed as for the respectively; methanol (<0.5% final concentration) was methadone incubations. used to dissolve chlorzoxazone, diazepam, fluoxetine, ketoconazole and troleandomycin. Omeprazole was prepared in a mixture of water with pH adjusted to 10.5
Data analysis with sodium hydroxide, and methanol (final methanol
The rates of EDDP formation from the kinetic studies concentration 0.5%). Incubations containing equivalent (V ) were expressed as nmol mg
, and amounts of diluents were always used as controls. When Eadie-Hofstee ( V /Substrate concentration vs V ) plots compared with control reactions containing no diluent, were constructed, and a single enzyme Michaelis-Menten control reactions containing methanol or 0.5% dimethylkinetics equation was fitted to the unweighted data using sulphoxide showed greater than 90% activity, as did the nonlinear least-squares regression analysis (Regression, pH 10.5 water containing 0.5% methanol, while those Blackwell Scientific Publications, Oxford, UK) giving containing 1.7% dimethylsulphoxide showed greater than estimates of V max and K m , where V max is the maximum 80% activity. Control incubations containing inhibitors reaction velocity and K m is the substrate concentration at alone did not produce any chromatographic peaks that which the reaction rate is half V max . Intrinsic clearance interfered with the quantification of EDDP.
( inhibitors between rac-, (R)-, and (S)-methadone were Substrates were incubated at a concentration equal to assessed using paired t-tests. Statistically significant differtheir respective K m values for that particular liver sample.
ences in percentage inhibition of the chemical inhibitors Antibodies specific for CYP3A4 and CYP2E1 were used compared to control reactions was assessed with oneat two titres (2 ml/100 mg and 8 ml/100 mg microsomal tailed t-tests. Differences were considered significant protein) in duplicate. Antibodies were used according to when P<0.05. the manufacturers directions. Incubation conditions did not alter from the kinetic study.
Results
Metabolism studies with expressed CYP isoforms Metabolic profile
No chromatographic peaks corresponding to either of Microsomes from human lymphoblastoid cells containing expressed CYP3A4, CYP2D6 and CYP2C19 were used the p-hydroxy methadone diastereomers or EMDP were observed in any incubation containing rac-, (R)-or (S)-methadone. The only metabolite observed was EDDP, whose formation was NADP-dependent, and was localized to the microsomal fraction as no EDDP formation was observed in incubations of methadone in the cytosolic liver fraction ( preliminary investigations, results not shown).
Kinetics of EDDP formation
Eadie-Hofstee plots were found to be linear in all cases ( Figure 2 ) and a single enzyme Michaelis-Menten kinetic equation was fitted to the data ( (Table 1) .
Inhibition with chemical inhibitors
EDDP formation from rac-, (R)-, and (S)-methadone was significantly ( P<0.05)
inhibited by ketoconazole at 100 mm (75±18%, 83±11%, 78±4% inhibition), 1 mm (43±12%, 43±10%, 46±14% inhibition) and 0.1 mm (8±2%, 8±3%, 7±5% inhibition); troleandomycin at 100 mm (45±7%, 44±11%, 43±10% inhibition), 10 mm (22±11%, 19±10%, 21±12% inhibition); sulphaphenazole at 100 mm (18±6%, 26±4%, 14±7% inhibition); DDC at 100 mm (44±12%, 44±11%, 45±11% inhibition); omeprazole at 100 mm (29±13%, 29±7.3%, 23±11% inhibition) and fluoxetine at 100 mm (56±10%, 53±6%, 50±13% inhibition) compared with control reactions (Figure 3 ). In addition EDDP formation from (S)-methadone was significantly ( P=0.006) inhibited by chlorzoxazone (15±2% inhibition) (Figure 3) . The inhibition of EDDP formation was not statistically significantly different between the three substrates in all cases ( P >0.05, Figure 3) . The other chemical inhibition experiments did not result in significant ( P >0.05) inhibition of the formation of EDDP from rac-, (R)-, and (S)-methadone compared with control reactions (Figure 3 ). inhibited by both the 8 ml (43±2% and 49±1%) and 2 ml (20±3% and 19±3%) titres of the CYP3A4 specific antibodies, respectively. CYP2E1 specific antibodies did not inhibit this reaction. 
Metabolism by expressed CYP isoforms
When corrected for CYP450 content, expressed CYP3A4 and CYP2C19 catalysed the N-demethylation of (R)-and (S)-methadone at similar rates, while the formation of EDDP with expressed CYP2D6 was not observed (Figure 4) .
Secondary metabolism of EDDP
Incubation of EDDP at a single high concentration (1 mm) resulted in <1% formation of EMDP.
Discussion
Substantial interindividual variability in rac-methadone disposition has hindered its more widespread use in pain management [24] and can pose difficulties in dosage regimen designs in opioid dependence treatment. The 4-5 fold range in CL int observed for the formation of To date this is the first report examining the 5  66  77  66  200  252  185  332  305  354  16  63  62  52  144  169  180  438  365  289  21  27  24  26  188  170  170  142  142  155  22  62  70  58  126  152  141  494  462  410  23 stereoselectivity in the N-demethylation of methadone in In the present study p-hydroxy methadone and EMDP were not formed, suggesting that they are likely to be human liver microsomes. The V max for the formation of EDDP from (S)-methadone was significantly lower than minor metabolites in humans, supporting the data of Sullivan and Due [8] . for (R)-methadone, however, the magnitude of the difference was small (mean difference: 6.2 nmol mg −1 CYP3A4 has been reported to be involved in the Ndemethylation of rac-methadone, although the contriprotein h −1 ) and less than 15%. There were no significant differences between (R)-and (S)-methadone observed bution of other isoforms could not be ruled out [11, 12, 14] . Our results confirm the role of CYP3A4 in this for K m , even though the chiral carbon is in close proximity to the site of oxidation. Similarly, there was metabolic pathway as troleandomycin, ketoconazole and a selective 3A4 antibody caused concentration dependent no significant difference between (R)-and (S)-methadone for CL int , indicating that it is unlikely that there would inhibition. Approximately 20% inhibition with sulphaphenazole (100 mm) was observed indicating that be stereoselectivity in this metabolic pathway in vivo. These data are supported by the expressed enzyme and CYP2C9 may also mediate this reaction, in support of Moody and coworkers [14] who reported a mean of 57% inhibition data, which also did not indicate a clear difference between the two substrates. Rac-methadone inhibition of this pathway by the same concentration of sulphaphenazole. However, Iribarne and coworkers [11] K m and CL int were significantly different ( P<0.05) to those of (R)-methadone, but not (S)-methadone, found no inhibition with sulphaphenazole at 5 mm. The selective chemical inhibitors of CYP1A2, CYP2A6, although the magnitude of the differences were small (mean differences #15%). Interpretation of these data is CYP2C19, CYP2D6 and CYP2E1 had no effect indicating that these isoforms are unlikely to contribute difficult, as rac-methadone is a 151 mixture of the two enantiomers. As the two individual enantiomers do not substantially to EDDP formation. Heterologously expressed human CYP450 proteins differ in their affinity (K m ) then one would expect the K m of the racemate to be comparable. The observed have also been examined for their ability to Ndemethylate rac-methadone, and only CYP3A4 was greater CL int for rac-methadone compared with (R)-methadone appears to be due to the lower K m , as considered to be important [11, 14] . The current results agree with those above since formation of EDDP from V max values were similar.
Rac-MD ( R)-MD (S)-MD
The V max values are comparable with those reported (R)-and (S)-methadone by microsomes from human lymphoblastoid cells containing expressed CYP3A4 at by Iribarne and coworkers [11] in their study of racmethadone in a panel of 20 human liver microsomal velocities comparable to those in human liver microsomes were observed. Microsomes containing expressed preparations. However, they estimated the K m for racmethadone in three livers to be 545±258 mm, a result CYP2C19 were also found to catalyse the N-demethylation of (R)-and (S)-methadone at similar rates to indicating a low and highly variable affinity for the CYP450 isoform(s) mediating the formation of EDDP.
expressed CYP3A4. It is unlikely that CYP2C19 plays a major role in this reaction as, total CYP2C is expressed The results from the present study indicate very little variability in six human liver preparations with K m values in the human liver in amounts less than 50% of CYP3A [25, 26] , no correlation was found between for rac-, (R)-and (S)-methadone almost 3-fold lower than that reported by Iribarne and coworkers [11] .
(S)-mephenytoin hydroxylation and rac-methadone Ndemethylation reaction rates [11] and 100 mm Reasons for this difference are not apparent.
(S)-mephenytoin, a CYP2C19 inhibitor, caused no (R)-and (S)-methadone by # 50% which is consistent with its known CYP3A4 inhibitory action [23, 40, 41] . significant inhibition of EDDP formation.
There are several reports of either decreased racOmeprazole was found to inhibit EDDP formation from rac-, (R)-and (S)-methadone by #30%. This is consistent methadone plasma concentrations and/or concurrent complaints of opioid withdrawal symptoms by patients with its known affinity for CYP3A4 and CYP2C19 [42] [43] [44] . soon after commencement of therapy with known CYP3A inducers [27] [28] [29] [30] [31] . The present findings confirm
In conclusion, the N-demethylation of methadone in human liver microsomes is not stereoselective, and is the involvement of CYP3A4 in the metabolism of methadone and the potential for clinically important mediated predominantly by CYP3A, and possibly CYP2C19 and CYP2C9 to a minor extent. Thus, the drug-drug interactions.
Methadone has been shown to alter the metabolism of large interindividual variation reported for the pharmacokinetics of methadone may be due to variability in the several CYP2D6 substrates in vivo and in vitro [32] [33] [34] [35] . These results would appear to suggest that methadone is expression of these CYP isoforms, and the reported stereoselectivity in the clearance of methadone in humans metabolized by CYP2D6. However, the results of Iribarne and coworkers [11] , Moody and coworkers [14] and the is not due to partial intrinsic clearance by the Ndemethylation reaction. present study in which quinidine, a potent CYP2D6 inhibitor, elicited no inhibition of methadone N- [36]). These data indicate that, although methadone is a selective for CYP2E1, and probably reflects inhibition of CYP3A4 [37] . Iribarne and coworkers [11] reported that catalytic activities of CYP2E1-mediated reactions did not References correlate with rac-methadone N-demethylation, and more 1 Kristensen K, Christensen CB, Christrup LL. The mu1, recently rac-methadone did not inhibit CYP2E1-mediated mu2, delta, kappa opioid receptor binding profiles of reactions [12] . Chlorzoxazone (100 mm) had a minimal methadone stereoisomers and morphine. Life Sci 1995; 56: effect on (S)-methadone N-demethylation, and no effect 45-50. on rac-or (R)-methadone. These data indicate that however, Iribarne and coworkers [11] Fluoxetine inhibited the formation of EDDP from rac-,
